FDA Grants Full Approval for Pfizer's Paxlovid COVID-19 Treatment

The antiviral pill Paxlovid has received full approval from the FDA for high-risk adults with mild to moderate COVID-19.
Paxlovid reduces the risk of hospitalization or death by 86% and consists of two drugs taken together for five days.
The approval gives doctors more flexibility in prescribing Paxlovid, including the option of longer treatment courses.
The U.S. has 1.1 million courses of Paxlovid available for free, but Pfizer will sell the drug directly once supplies run out.
Paxlovid is the first pill for COVID-19 to receive full FDA approval though it remains available for children under emergency authorization.